Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Mechlorethamine: A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Lomustine: An alkylating agent of value against both hematologic malignancies and solid tumors.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Actuarial Analysis: The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Lung Neoplasms: Tumors or cancer of the LUNG.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Diagnostic Imaging: Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Systems Biology: Comprehensive, methodical analysis of complex biological systems by monitoring responses to perturbations of biological processes. Large scale, computerized collection and analysis of the data are used to develop and test models of biological systems.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Neurons: The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.Library Services: Services offered to the library user. They include reference and circulation.Libraries, MedicalHospitals, Voluntary: Private, not-for-profit hospitals that are autonomous, self-established, and self-supported.Patient Care Team: Care of patients by a multidisciplinary team usually organized under the leadership of a physician; each member of the team has specific responsibilities and the whole team contributes to the care of the patient.Hospitals, Proprietary: Hospitals owned and operated by a corporation or an individual that operate on a for-profit basis, also referred to as investor-owned hospitals.Accreditation: Certification as complying with a standard set by non-governmental organizations, applied for by institutions, programs, and facilities on a voluntary basis.Certification: Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.MaineSouth Australia: A state in south central Australia. Its capital is Adelaide. It was probably first visited by F. Thyssen in 1627. Later discoveries in 1802 and 1830 opened up the southern part. It became a British province in 1836 with this self-descriptive name and became a state in 1901. (From Webster's New Geographical Dictionary, 1988, p1135)Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.DeoxycytidineCell Line, Tumor: A cell line derived from cultured tumor cells.Hospitals, Teaching: Hospitals engaged in educational and research programs, as well as providing medical care to the patients.

Adenoviral gene transfer into the normal and injured spinal cord: enhanced transgene stability by combined administration of temperature-sensitive virus and transient immune blockade. (1/14907)

This study characterized gene transfer into both normal and injured adult rat dorsal spinal cord using first (E1-/E3-) or second (E1-/E2A125/E3-, temperature-sensitive; ts) generation of replication-defective adenoviral (Ad) vectors. A novel immunosuppressive regimen aimed at blocking CD4/CD45 lymphocytic receptors was tested for improving transgene persistence. In addition, the effect of gene transfer on nociception was also evaluated. Seven days after treatment, numerous LacZ-positive cells were observed after transfection with either viral vector. By 21 days after transfection, beta-galactosidase staining was reduced and suggestive of ongoing cytopathology in both Ad-treated groups, despite the fact that the immunogenicity of LacZ/Adts appeared less when compared with that elicited by the LacZ/Ad vector. In contrast, immunosuppressed animals showed a significant (P < or = 0.05) increase in the number of LacZ-positive cells not displaying cytopathology. In these animals, a concomitant reduction in numbers of macrophages/microglia and CD4 and CD8 lymphocytes was observed. Only animals that received LacZ/Adts and immunosuppression showed transgene expression after 60 days. Similar results were observed in animals in which the L4-L5 dorsal roots were lesioned before transfection. Gene transfer into the dorsal spinal cord did not affect nociception, independent of the adenovirus vector. These results indicate that immune blockade of the CD4/CD45 lymphocytic receptors enhanced transgene stability in adult animals with normal or injured spinal cords and that persistent transgene expression in the spinal cord does not interfere with normal neural function.  (+info)

Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. (2/14907)

Interleukin-12 (IL-12) is a potent antitumor cytokine, which induces and enhances the activity of natural killer (NK) cells, lymphokine activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). IL-12 also stimulates IFN-gamma production from both T cells and NK cells. In this study, we transfected methylcholanthrene-induced fibrosarcoma (MCA-D) with TNF gene and investigated the therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect is enhanced by systemic administration of recombinant IL-12 (rIL-12), in a murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL-12 showed slight or moderate inhibition of pre-established tumor. However, simultaneous application of the vaccine and rIL-12 resulted in complete eradication. The cytotoxicity of CTL against parental tumor cells was enhanced with the combination of the vaccine and rIL-12, and IFN-gamma production from spleen cells also increased synergistically. Our findings show that synergistic enhancement of CTL activity and IFN-gamma production could play an important role in the antitumor effect of combination therapy using TNF gene-transduced cancer vaccine and rIL-12.  (+info)

Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation. (3/14907)

Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71%. Including the 15 patients with microscopic disease, the local control rate was 73%. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas.  (+info)

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. (4/14907)

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P<0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P<0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (5/14907)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (6/14907)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Lymphomatoid granulomatosis following autologous stem cell transplantation. (7/14907)

Lymphomatoid granulomatosis (LYG) is a rare angio-destructive lymphoproliferative disorder (LPD) of uncertain etiology, with prominent pulmonary involvement. Recent studies indicate that LYG is an Epstein-Barr virus (EBV)-associated B cell LPD with large numbers of background reactive T lymphocytes (T cell-rich B cell lymphoma). Although the disease frequently, but not exclusively, occurs in various immunodeficiency states, it has not been reported in association with the transient immunosuppression following autologous bone marrow/peripheral stem cell transplantation (ABM/PSCT). We describe a patient who developed lymphomatoid granulomatosis of the lung approximately 2 weeks after high-dose chemotherapy and autologous peripheral stem cell transplantation for multiple myeloma. Although molecular studies showed no evidence of EBV genome in the biopsy material, the serologic profile with high IgM titers was suggestive of primary EBV infection. Complete radiologic remission occurred following reconstitution of the patient's immune response after a 2-week course of ganciclovir treatment. Despite the apparently low frequency of LPD (both LYG and EBV-associated post-transplant lymphoma) in the ABMT setting, we believe that it should be considered in the differential diagnosis of patients whose clinical course following ABMT is complicated by fevers, in the absence of an identifiable infectious process.  (+info)

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. (8/14907)

5-Fluorouracil (5-FU) is an effective enhancer of radiation therapy (RT) in head and neck cancers. Due to rapid, predominantly hepatic metabolism by dihydropyrimidine dehydrogenase (DPD) and suggested clinical benefit from prolonged drug exposure, 5-FU is commonly given by continuous infusion. Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing. We conducted a Phase I study of the safety and efficacy of eniluracil given with oral 5-FU in patients receiving concurrent RT for recurrent or advanced squamous cell carcinomas of the head and neck. Thirteen patients with recurrent, metastatic, or high-risk (defined as an expected 2-year survival rate of <10%) head and neck cancer were enrolled and treated with concomitant chemoradiotherapy on an every-other-week schedule. Eniluracil at a fixed dose [20 mg twice a day (BID)] was given for 7 consecutive days (days 1-7). 5-FU and RT were given on 5 consecutive days (days 2-6). One patient was treated with once-daily RT (2.0 Gy fractions). The remaining patients received hyperfractionated RT (1.5-Gy fractions BID). The initial dose of 5-FU was 2.5 mg/m2 given BID. Dose escalation in patient cohorts was scheduled at 2.5-mg/m2 increments, with intrapatient dose escalation permitted. Lymphocyte DPD activity and serum 5-FU and uracil concentrations were monitored during two cycles. DPD activity was completely or nearly completely inactivated in all patients. Sustained, presumed therapeutic concentrations of 5-FU were observed at a dose of 5.0 mg/m2 given BID. Cumulative dose-limiting myelosuppression (both neutropenia and thrombocytopenia) was observed during the fourth and fifth cycles following administration of 5.0 mg/m2 5-FU BID. One patient died of neutropenic sepsis during cycle 4. Other late cycle toxicities included diarrhea, fatigue, and mucositis. Grade 3 mucositis was observed in 4 patients, but no grade 4 mucositis or grade 3 or 4 dermatitis was observed. A second patient death occurred during cycle 1 of treatment. No specific cause of death was identified. The study was subsequently discontinued. Cumulative myelosupression was the significant dose-limiting toxicity of oral 5-FU given with the DPD-inactivator eniluracil on an every-other-week schedule. Clinical radiation sensitization was not observed, based on the absence of dose-limiting mucositis and dermatitis. Alternative dosing schedules need to be examined to determine the most appropriate use of eniluracil and 5-FU as radiation enhancers.  (+info)

*Michael L. J. Apuzzo

"Combined Modality Therapy of Central Nervous System Tumors". ISBN 9783540006275. Hoh DJ, Liu CY, Pagnini PG, Yu C, Wang MY, ... Chained lightning: part III--Emerging technology, novel therapeutic strategies, and new energy modalities for radiosurgery. ... technology transfer and the implementation of advanced technologies to the therapy of brain diseases. In 1991, he was appointed ...

*Precocious puberty

"Intracranial choriocarcinoma causing precocious puberty and cured with combined modality therapy". Journal of Paediatrics and ...

*Total body irradiation

December 1983). "Intensive combined modality therapy including low-dose TBI in high-risk Ewing's Sarcoma Patients". Int. J. ... In addition to its use in bone marrow transplantation, total body irradiation has been explored as a treatment modality for ... August 2003). "High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two ...

*Thyroid lymphoma

Combined modality therapy is the most common approach for the initial treatment of thyroid lymphomas. The CHOP regimen ( ... However, it is suggested to perform radiation therapy only for MALT resulting a 96% complete response, with only a 30% relapse ...

*Intraoperative electron radiation therapy

Haddock MG1, Miller RC, Nelson H. Combined modality therapy including intraoperative electron irradiation for locally recurrent ... Radiation Therapy Intraoperative Radiation Therapy (Proceedings of the Third International Symposium on Intraoperative ) edited ... Abe M. History of Intraoperative radiation therapy. In:Debelbower RR, Abe M (eds) Intraoperative radiation therapy. CRC, Boca ... Frontiers of Radiation Therapy and Oncology vol 31. Editor(s): Vaeth, J.M. (Mill Valley, Calif.) New techniques in electron ...

*Henry Harrington Janeway

"Fundamental Mechanisms in Combined Modality Therapy of Cancer" 1976 Audrey Evans, M.D., Philadelphia, Pennsylvania - "Pediatric ... His report on Radium Therapy in Cancer, at the Memorial Hospital (1915-1916), which appeared in book form in 1917 was the most ... 81-82 Janeway, M.D., Henry Harrington (August 1917). Radium Therapy in Cancer at the Memorial Hospital New York. New York: Paul ... Janeway, H. H., Barringer, B. S., & Failla, G. (1915). Radium Therapy. Cancer at Memorial Hospital, 16. Janeway, H. H. (1918). ...

*Minesh Mehta

... combined modality therapies, altered fractionation, cost-effectiveness, and outcomes research. He has run numerous ... Combined modality treatment of tumors of the CNS and thorax, as well as pediatric neoplasms: integrating systemic chemotherapy ... Effects of therapies on cognition and developing methods to improve neurocognitive function. Medical director, the Maryland ... Chair, Brain Tumor Committee, Radiation Therapy Oncology Group. "Faculty Profiles: University of Maryland School of Medicine". ...

*Cancer research

... hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy. Starting in the mid-1990s, the ... is a prostate cancer vaccine Newer forms of chemotherapy Gene therapy Photodynamic therapy Radiation therapy Reoviridae ( ... Reolysin drug therapy) Targeted therapy Natural killer cells can induce immunological memory. Research is being developed to ... Radiation therapy took hold in the 1900s. Chemotherapeutics were developed and refined throughout the 20th century. The U.S. ...

*Targeted therapy

... the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy. ... Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for ... the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy (and thus ... Targeted therapy Targeted drug delivery Targeted molecular therapy for neuroblastoma Targeted therapy of lung cancer Treatment ...

*Prostvac

... to evaluate the potential clinical benefit of combining PROSTVAC with different treatment modalities such as hormonal therapies ... Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW (2014). "Androgen deprivation therapy sensitizes prostate cancer cells ... Based on non-clinical data supporting the scientific rationale for combination therapy with PROSTVAC, additional clinical ... "ABO blood type correlates with survival on prostate cancer vaccine therapy". Oncotarget. 6 (31): 32244-56. doi:10.18632/ ...

*Wilderness therapy

... is an adventure-based therapy treatment modality for behavior modification and interpersonal self-improvement, combining ... There is no one standardized model for the therapy, since many models of wilderness therapy are reflective of different ... Media related to Wilderness therapy at Wikimedia Commons Learning materials related to Wilderness therapy at Wikiversity The ... therapy and group activities in an unfamiliar context away from home, wilderness therapy encourages the development of healthy ...

*Treatment of lung cancer

It is possible that the two modalities have a synergistic effect and patients may benefit from combined treatment. Prior to the ... An animal tumor model demonstrated improved survival after combined treatment with RFA and radiation therapy compared to either ... Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology 2005. ... July 2006). "Percutaneous Image-guided Thermal Ablation and Radiation Therapy: Outcomes of Combined Treatment for 41 Patients ...

*Chemotherapy

Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or ... Systemic therapy is often used in conjunction with other modalities that constitute local therapy (i.e. treatments whose ... Importantly, the use of drugs (whether chemotherapy, hormonal therapy or targeted therapy) constitutes systemic therapy for ... In regard to the potential benefit that drug-resistant cells can be recruited for effective therapy by combining chemotherapy ...

*Anal cancer

This "combined modality" approach has led to the increased preservation of an intact anal sphincter, and therefore improved ... Current gold-standard therapy is chemotherapy and radiation treatment to reduce the necessity of debilitating surgery. ... Some patients have fecal incontinence after combined chemotherapy and radiation. Biopsies to document disease regression after ...

*Lymphedema

Lymphatic liposuction combined with controlled compression therapy was more effective than controlled compression therapy alone ... A 2002 study showed patients receiving the combined modalities of manual lymphatic drainage (MLD) with complete decongestive ... Well-controlled clinical trials conducted from 1993 to 2014 showed SAL, combined with controlled compression therapy (CCT), to ... Brorson H, Svensson H (September 1998). "Liposuction combined with controlled compression therapy reduces arm lymphedema more ...

*Joaquín Gómez Mira

Mira, J.G.: Combined Modality Treatment for Small Cell Lung Cancer. Chapter in Combined Chemotherapy and Radiotherapy in ... He was elected Head of the Radiotherapy department of the Cancer Therapy & Research Center every year between 1993 and 2007. He ... He was named Director of Radiotherapy in the Cancer Therapy & Research Center, under the National Cancer Institute, where he ... McCracken, J.D. and Mira, J.G.: Concurrent Chemotherapy and Radiation Therapy for Limited Small Cell Lung Cancer. Monograph, ...

*Anaplastic thyroid cancer

Palliative treatment consists of radiation therapy usually combined with chemotherapy. New drugs, such as fosbretabulin (a type ... anaplastic thyroid cancer is highly unlikely to be curable either by surgery or by any other treatment modality, and is in fact ... or therapy, or both in the remainder. Anaplastic thyroid cancer is extremely aggressive; in most cases death occurs in less ...

*Medically unexplained physical symptoms

A combined therapeutic approach which is at least twice as effective as other therapeutic modalities published to date is ... "Cognitive-behavior therapy for medically unexplained symptoms: A critical review of the treatment literature". Behavior Therapy ... Steele RE, de Leeuw E, Carpenter D. "A novel and effective treatment modality for medically unexplained symptoms" J Pain ... "A novel and effective treatment modality for medically unexplained symptoms". The next best documented approach is cognitive ...

*Tamra Mercieca

Combining all of these techniques (along with extensive study into a range of other psychological healing modalities) and ... Mercieca also applies her healing therapy to sexual issues, being invite to be Sexpo Australia's Relationship Expert (2013-2015 ... developing some of her own, she labelled her new therapy, Naked Therapy, going on to launch her own company Getting Naked Pty ... Time-Line Therapy, Hypnosis and Wholebrain Intelligence (she is also accredited with the relevant boards in America). It was ...

*Psychomotor patterning

The therapy normally lasts for 5 minutes and is repeated at least 4 times a day. Full treatment programs typically contain a ... The treatment modality of patterning was developed in the 1960s by Glenn Doman and Carl Delacato. Robert Doman, the nephew of ... range of exercises combined with sensory stimulation, breathing exercises designed to increase oxygen flow to the brain, and ... and treatment primarily focuses on non-invasive physical therapy in each of these stages. In one such stage, the homolateral ...

*Psychotherapy

This includes the modalities dance therapy, drama therapy, art therapy, music therapy, writing therapy, among others. ... meseron therapy and systemic therapies based on the Ubuntu philosophy. Integrative psychotherapy is an attempt to combine ideas ... multimodal therapy, and therapies for specific disorders including PTSD therapies such as cognitive processing therapy and EMDR ... Today group therapy is used in clinical settings and in private practice settings. Expressive therapy is any form of therapy ...

*European Society for Hyperthermic Oncology

... of the biological effects of heat in the treatment of cancer either alone or combined with other cancer treatment modalities. ... biological and clinical sciences relating to the use of hyperthermia in cancer therapy and to facilitate integration and ...

*Polyestradiol phosphate

It is also used in women to treat breast cancer and in hormone therapy for low estrogen levels or menopausal symptoms. It is ... PEP has been compared to combined androgen blockade (CAB; castration plus flutamide) for the treatment of prostate cancer in a ... At 18.5 months, there was no difference in survival or cardiovascular toxicity between the two treatment modalities. These ... PEP is used as an intramuscular injection for estrogen therapy of prostate cancer in men. It is also used to treat breast ...

*Iliotibial band syndrome

Massage therapy, and many of its modalities, can offer relief if symptoms arise. Chondromalacia patellae Patellofemoral pain ... The continual rubbing of the band over the lateral femoral epicondyle, combined with the repeated flexion and extension of the ... Manual Therapy. 12 (3): 200-8. doi:10.1016/j.math.2006.08.004. PMID 17208506. Barber, F. Alan; Sutker, Allan N. (August 1992 ...

*Autologous immune enhancement therapy

These two modalities affect not only the cancer affected cells, but also the normal cells Now in AIET, specific types of cells ... has proven that the cell based immunotherapy when combined with conventional treatment the efficacy improves by 20-30%. A ... This is the mechanism by which AIET is effective in cancer therapy. Adoptive Immuno cell therapy of cancer was first introduced ... Autologous immune enhancement therapy (AIET) is a treatment method in which immune cells are taken out from the patient's body ...

*Cervical cancer

... can be treated with radical hysterectomy with removal of the lymph nodes or radiation therapy. Radiation therapy is given as ... Imaging modalities such as ultrasound, CT scan and MRI have been used to look for alternating disease, spread of tumor and ... More recently, CIN2 and CIN3 have been combined into CIN2/3. These results are what a pathologist might report from a biopsy. ... Treatment of cervical cancer may consist of some combination of surgery, chemotherapy, and radiation therapy. Five-year ...
The abscopal effect is mediated by a systemic anti-tumor immune response and reflects the regression of non-irradiated metastatic lesions at a distance from the primary site of irradiation. This review will focus on understanding the biological rationale behind the abscopal effect of radiotherapy (RT), which has a recently renewed interest as a result of the successes achieved with immunotherapy and RT in combination. Both RT and immunotherapy are standard components of modern treatment regimens. Combination of these two modalities results in an increased response in the irradiated lesions themselves and the metastatic regions distant from the site of irradiation. We will summarize the abscopal effect of radiotherapy, in particular, the synergistic effect of RT and immunotherapy.
The analysis was based on a total of 468 patients with a median age of 66 years; 64% were younger than age 70, 19% were aged 70 to 75, and 17% were older than age 75. Among all patients, 82% were male. Approximately 94% had transitional cell carcinoma; 61% had clinical stage T2 tumors, and 35% had clinical stage T3. Median follow-up was 4.3 years for all patients and 7.8 years among 205 survivors.. Seventy-two percent of patients had a complete response to combined-modality therapy. The 5- and 10-year estimated overall survival rates were 57% and 36%, respectively; 5- and 10-year estimated disease-specific survival rates were 71% and 65%.. The majority of local failures in the bladder were non-muscle invasive, with an estimated 5- and 10-year incidence of 31% and 36%. The 5- and 10-year estimates for muscle-invasive failure rates were 13% and 14%, and 5- and 10-year estimates of distant metastases were 31% and 35%.. "This recurrence pattern underscores the need for careful post-treatment ...
In this study, we show in breast and colon carcinoma models that fractionated local radiotherapy to one palpable tumor can synergize with CTLA-4 blockade to induce antitumor T-cell immunity and inhibit a second palpable tumor outside the radiation field. This abscopal effect was not seen with radiotherapy alone. Although localized tumor irradiation by itself has been shown to enhance the generation of tumor-specific T cells in both preclinical models and patients, the therapeutic effects of this response remain undetermined (3, 19). Clearly, irradiation to the primary tumor was required in our models to induce growth inhibition of the secondary tumors outside the field because CTLA-4 blockade by itself was ineffective (Figs. 2 and 6). This is consistent with the hypothesis that radiation-induced immunogenic tumor cell death as well as its induction of danger signals contribute to generate an in situ vaccine (20-22). Whereas the response generated is not sufficient to be therapeutically ...
Results of radiation given to patients with AIDS-related high-grade CNS lymphoma have been disappointing, with short survival times due to infection complications. However, complete response has been documented after radiation in some patients. High-dose MTX will be used to improve the possibility of a greater antineoplastic response than that obtained by radiation alone. Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone to life-threatening opportunistic infections or relapse of lymphomatous disease within the CNS. Accordingly, AZT will also be used in an attempt to alter the overall natural history of the disease.. Radiation begins on day 1 of therapy. Patients receive dexamethasone orally (PO) or by intravenous injection (IV) on days 1-10. MTX IV over 6 hours weekly for a total of 4 doses starts 1 week after completion of the cranial radiation. Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over ...
Results of radiation given to patients with AIDS-related high-grade CNS lymphoma have been disappointing, with short survival times due to infection complications. However, complete response has been documented after radiation in some patients. High-dose MTX will be used to improve the possibility of a greater antineoplastic response than that obtained by radiation alone. Since the underlying immunodeficiency state is not affected by therapy directed against the lymphoma, patients are still prone to life-threatening opportunistic infections or relapse of lymphomatous disease within the CNS. Accordingly, AZT will also be used in an attempt to alter the overall natural history of the disease.. Radiation begins on day 1 of therapy. Patients receive dexamethasone orally (PO) or by intravenous injection (IV) on days 1-10. MTX IV over 6 hours weekly for a total of 4 doses starts 1 week after completion of the cranial radiation. Leucovorin (LCV) IV or PO begins 6 hours after MTX has been completed over ...
Generating and grading the abscopal effect: proposal for comprehensive evaluation of combination immunoradiotherapy in mouse models
Generating and grading the abscopal effect: proposal for comprehensive evaluation of combination immunoradiotherapy in mouse models
The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. But in a surprising new finding, radiation combined with chemotherapy did not ...
Combined-modality approaches for the treatment of non-small-cell lung cancer (NSCLC), head and neck cancer, and esophageal cancer offer survival benefits by improving locoregional control and treating micrometastatic disease. The taxanes are active, tolerable drugs in these solid tumors and have radiation-sensitizing activity. 1
Health,...Study confirms effectiveness of widely used approach experts say ...MONDAY Dec. 15 (HealthDay News) -- Men with locally advanced prostate...The addition of radiotherapy kept patients healthy much longer the Sw... The study will change practice in the treatment of locally advanced o...,Radiation,Plus,Hormone,Therapy,Cuts,Prostate,Cancer,Deaths,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
ABSTRACT: The multimodal therapy of ADHD with comorbidities proved its efficacy în comparison with the unimodal therapies. We will present the preliminary results of the first nine months of multimodal therapy, which has been applied on a number of 18 children and adolescents with ages between 8 and 17 years. ...
Chemotherapy, when combined with radiotherapy and/or surgery in the treatment of patients with head and neck cancer, appears to be most efficacious if it is given concurrently with radiotherapy. Concurrent chemotherapy and 1
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D: Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys 97(4): 687-699, March 2017 ...
More than 400 respected luminaries explore todays most effective strategies for managing every type of cancer by stage of presentation - discussing the role of all appropriate therapeutic modalities as well as combined-modality treatments. This multidisciplinary approach will help your cancer team collaboratively face the toughest clinical challenges and provide the best possible care for every cancer patient.
As a first step toward developing quantitative models, investigators recently developed a mathematical framework to simulate the systemic dissemination of T cells activated in response to focal therapy.
Primary Endpoint: To determine the maximum tolerated dose (MTD) of vorinostat + radiation therapy (RT) in patients with locally advanced pancreat
Improved dose tracking and a more multimodal approach are just a few of the ways treatment planning systems are delivering higher-quality radiation therapy
Loco-regional recurrences after intial surgery in patients with esophageal cancer remain a serious challenge to clinical oncologists. The NCCN Guidelines pointed out that a highly selected group of patients with local-regional tumor recurrence after initial surgery may be considered fit and able to tolerate concurrent radio-chemotherapy with a potential for cure [18]. In a line with the previous studies, our data indicated that salvage concurrent radio-chemotherapy was an active and promising treatment strategy for such patients, reaching a median OS of 13.3 months with tolerable side-effects.. The present protocol of concurrent radio-chemotherapy was completed in 74% (37/50) of the patients, and no serious treatment related toxicities were observed. The tumor response rate was nearly 72% in R-TP and R-FP group respectively, with a 3-year survival rate of 14%. These results are very similar to those reported in previous studies [13, 15]. Yamashita et al.[13] reported the results of radiotherapy ...
For all 250 patients, the overall median survival was 27 months, the cause-specific survival was 27 months, the local progression-free survival was 32 months, and distant metastasis-free survival was not achieved; and the respective 5-year survival rates were 27%, 32%, 45%, and 68%. CF achieved significantly inferior survival than either HFX RT alone or HFX RT-Pac/C (P = .0332 and P = .0013, respectively), and no difference was observed between the 2 HFX RT regimens (P = .1934). Only acute hematologic high-grade toxicity (grade ≥3) was more frequent with HFX RT-Pac/C than with either RT alone, whereas other toxicities were similar between the 3 treatment groups. ...
article{4430146, abstract = {Purpose: Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET) scan could be used to adapt treatment. Therefore, we started the randomized EORTC/LYSA/FIL Intergroup H10 trial evaluating whether involved-node radiotherapy (IN-RT) could be omitted without compromising progression-free survival in patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard combined-modality treatment. Patients and Methods: Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible. Here we report the clinical outcome of the preplanned interim futility analysis scheduled to occur after documentation of 34 events in the early PET-negative group. Because testing for futility in this noninferiority trial corresponds to testing the hypothesis of no difference, a ...
Results Out of the 12 patients in the study, 6 did not receive radiotherapy either because they elected for subsequent radical surgery (3 patients) or were unfit for further treatment and underwent close follow-up (3 patients).. In the radiotherapy group, 2 patients had pre-op Long-Course Chemo-radiotherapy (LCCRT) with a good partial response, 2 were included in the national TEM and Radiotherapy in Early Rectal cancer (TREC) trial and had pre-op Short Course radiotherapy (SCRT) and 2 had adjuvant LCCRT + Papillon contact radiotherapy following TEM.. Median follow-up was 20 months. Patients not undergoing radial surgery had 3 monthly MR and sigmoidoscopy for 1 year and 6 monthly MR and sigmoidoscopy for a further 2 years.. In the no-radiotherapy group, 1 of the 3 patients who underwent subsequent radical surgery had involved mesorectal lymph nodes and 1 of those undergoing close follow-up without radical surgery developed mesorectal nodal recurrence. In radiotherapy group 1 patient, in the TREC ...
Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.
Selected high-risk patients with head and neck squamous cell carcinoma receive postoperative radiation therapy (RT), with or without concurrent chemotherapy, following primary surgical resection with the aim of improving locoregional control and surv
PubMed journal article [Combined-modality therapy for 150 cases of early-stage Hodgkins lymphoma were found in PRIME PubMed. Download Prime PubMed App to iPhone or iPad.
Positron emission tomography using fluoro-deoxy-glucose has demonstrated added value in the clinical management of patients with colorectal cancer [6]. This includes primary staging, detection of recurrence, prediction of individual prognosis, therapy response, and evaluation of treatment response as assessed in this investigation [8].. The interest in FDG-PET to assess tumour response to CRT began in the early 1990 s. Rectal cancer is a disease model of particular interest, not only for its high incidence, but also because an accurate and non-invasive method to evaluate response to preoperative CRT could lead to patients selection for minimally invasive surgical approaches or even selection of candidates for additional chemotherapy and observation without any kind of surgery [2, 3].. Experts at the Memorial Sloan-Kettering Cancer Center reported a pioneer prospective assessment of LARC response to preoperative CRT using FDG-PET in 2000 [9]. Today, literature is mixed in regard to the ability ...
The survival of children with non-Hodgkins lymphoma (NHL) has improved in the recent past through the systematic application of intensive therapy employing involved field radiation plus combinations...
Prognosis of patients who present with metastasized rectal cancer is poor. Without treatment, median survival is estimated at six months. Treatment options are available for the primary tumor and the metastatic disease. The primary tumor may be resected or treated with radiation therapy. Resection of the primary tumor is controversial, as it may not improve the quality of life in patients with a poor prognosis due to the metastatic disease. As the majority of patients with primary stage IV rectal cancer present with a locally advanced primary tumor, resection of the primary tumor would necessitate preoperative radiation therapy. Metastatic disease may respond to chemotherapy. In recent years, advances in chemotherapy have increased the response rate to 40 percent. Some patients presenting with liver or lung metastases are candidates for resection of their metastatic disease. Neoadjuvant chemotherapy may increase the fraction of patients with resectable metastatic disease, or may allow for ...
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-ener
In lieu of an abstract, here is a brief excerpt of the content: 136 CHAPTER 4 Radiation Therapy and Surgery Radiation therapy, like chemotherapy, is intended to selectively kill malignant cells while sparing normal cells as much as possible. Like chemotherapy, radiation therapy (also called radiotherapy) is most active against rapidly dividing populations of cells. Unlike most forms of chemotherapy, radiation can be applied locally, to specific areas of the body, rather than spreading throughout the entire body via the bloodstream. Radiation therapy may be used alone to treat people with localized lymphocytepredominant Hodgkin lymphoma or localized indolent NHL, but it is more commonly used in combination with chemotherapy (a form of combined modality treatment). Combined modality therapy is most frequently used to treat localized disease, generalized disease in which there is a specific bulky component, or an area of localized disease that remains after chemotherapy treatment. Combined modality ...
Cancer is a systemic (throughout the body) disease, no matter what your doctor tells you. Telling patients based on post-operation scans that we got it all is not the truth. Most cancers have been growing and spreading for 5 to 10 years before they are detected and diagnosed. Billions of cancer cells must be present to show up on any scan. Surgery can spread cancer. The word cure in oncology circles has up to fifty different definitions. The only real cure is the one where you live long enough to die from something other than cancer. These survivors are strong, and most utilize a protocol to treat cancer everywhere in their body, rather than relying solely on local surgery, local radiation, and/or chemotherapy." ~ Dr. Bruce West. ...
Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the individual patient. Mechanistic data on treatment toxicity at the patient level are scarce; hence, probabilistic and translational linkages among different layers of data information, all the way from cellular targets of the therapeutic exposure to tissues and ultimately the patients organ systems, are required. Throughout all of these layers, untoward treatment effects may be viewed as perturbations that propagate within a hierarchically structured network from one functional level to the next, at each level causing disturbances that reach a critical threshold, which ultimately are manifested as clinical adverse reactions. Advances in bioinformatics permit compilation of information across the various levels of data organization, presumably enabling integrated systems biology-based prediction of treatment safety. In view of the complexity of biological responses to cancer
During high-dose chemotherapy, the patient receives high doses of chemotherapy, and possibly radiation therapy, in order to kill the cancer cells. Whi
Surgery and radiation are often used together in more advanced lesions. As combined treatment has evolved, surgery with postoperative radiation therapy is most often employed. Recent advances in reconstructive surgery have further improved functional and cosmetic outcomes.. In select instances, promising results are being obtained with combined chemotherapy and radiation therapy in an effort to avoid surgical resection.. ...
This unit (1) provides background into understanding how agents that target specific molecules or receptors (molecular‐targeted agents), in particular, agents affecting the tumor vasculature (perivasculature network in tumors), interact with and modify radiation therapy; (2) details factors affecting interpretation of results in murine tumor model experiments utilizing radiation therapy and drug combinations; and (3) provides specific protocols for the application of radiation therapy, both alone and in combination with chemotherapy and/or molecular‐targeted agents
We are thrilled to offer a wide range of the most advanced modalities that speed the healing process in conjunction with appropriate manual treatments
Preoperative radiation therapy has shown to be of benefit for the prevention of local recurrence rates in rectal cancer patients (11, 12). Long-course preoperative chemoradiotherapy is of benefit in stage T3/T4 rectal cancer patients, and long-course preoperative chemoradiation is the standard of care in the United States (27). However, considering the extensive morbidity of preoperative radiation therapy (13-15), it is of great importance to identify patients with a low risk of local recurrence in which radiation therapy is redundant. With this intention, the current study was done in patients with stage III rectal cancer, as these patients are at the highest risk for local recurrence (12). Our results show that biochemical detection of caspase-3 levels can be used as a marker to identify patients with a very high probability for local cure with surgery alone.. To select patients who can be refrained from preoperative radiation therapy, a marker should provide accurate prediction of clinical ...
When you donate blood or platelets at the Kraft Family Blood Donor Center at Dana-Farber Cancer Institute and Brigham and Women's Hospital, or give blood on board the Dana-Farber Cancer Institute/Brigham and Women's Hospital Blood Mobile, you are making a life-saving difference for patients in need - right here in our community.
The skin rash by EGFRI is thought to be the direct consequence of the EGFR blockade in basal epidermal keratinocytes as well as the outer root sheath of hair follicles, leading to a local growth arrest and consecutive inflammation. Its occurrence may be a pharmacodynamic marker of the drug action and has been proposed as surrogate parameter of tumour response [9, 10].. EGFRI are increasingly used in parallel to, or, at least, in short sequence to radiotherapy. For example, combined treatment with cetuximab and radiotherapy has been shown to improve locoregional control in patients with squamous cell carcinoma of the head and neck in a phase 3 trial [1]. Whereas the administration of cetuximab led to a significant amount of EGFRI-induced skin rashes in the combined treatment group (8.2% vs. 0.5%, p , 0.001), no statistically significant exacerbation of radiation dermatitis was reported (23 vs. 18% grade 3-5 reactions, p = 0.27).. In recent times, however, accumulating case reports reveal grade ...
A major objective of the second Intergroup Rhabdomyosarcoma Study (IRS-II) (1978 to 1984) was to preserve the bladder without compromising the survival of children with localized genitourinary sarcomas arising in or near the bladder. After incisional biopsy, 109 patients with localized, gross residual sarcoma of the prostate (43 patients), bladder (43 patients), vagina (20 patients), or cervix/uterine corpus (3 patients) were treated with vincristine, dactinomycin, and cyclophosphamide (VAC). After two to four drug courses, radiation therapy and/or surgery were used to treat patients with residual or recurrent tumor. The 3-year survival rate of patients treated on this primary chemotherapy regimen (70%) was similar to that of the primary surgery regimens of IRS-I (78%; P = 0.46), but the 3-year disease-free survival rate was significantly inferior (52% versus 70%; P = 0.02). Since the IRS-II encouraged bladder preservation at the onset of therapy, the percentage of patients with bladder and ...
Physicians, researchers, and scientists at Dana-Farber Cancer Institute and Brigham and Womens Hospital have launched one of the nations most comprehensive personalized cancer medicine initiatives.
Background: Radiotherapy (RT) is used for to treat unresectable locally advanced non-small cell lung cancer (NSCLC). For better disease control, RT has recently been combined with chemotherapy (CTx) in a variety of ways. This study examined the most effective combination methods of CTX and RT against NSCLC.. Material and Methods: Human lung cancer cell line (NCI-H520) and various chemotherapeutic agents (paclitaxel, docetaxel, gemcitabine, and cisplatin) were used in this study. The radiation doses used were 0, 2, 4 and 8 Gy. After processing of various combinations according to the radiation dose and concentrations of chemotherapeutic agents, the level of cell survival was quantified by a MTT assay. The combination index was calculated using the Chou and Talalay method on Calcusyn software and used to examine the synergism between CTx and RT.. Results: Among the various combinations of chemotherapeutic agents and radiation doses, concurrent chemoradiation therapy (CCRT) led to the highest rate ...
The ASCO Endorsement Panel emphasized the potential benefits of chemotherapy for women with high-risk early-stage or advanced disease. The GOG-122 trial compared whole-abdominal radiation therapy with doxorubicin and cisplatin chemotherapy in women with stage III or IV endometrial cancer and ≤ 2 cm of postoperative residual disease. Stage-adjusted results suggested that chemotherapy was associated with higher progression-free and overall survival, but also higher rates of acute toxicity.12 In the JGOG 2033 (Japanese Gynecologic Oncology Group) trial, women with stage IC to IIIC endometrial cancer were randomly assigned to pelvic radiotherapy or cyclophosphamide, doxorubicin, and cisplatin chemotherapy. The overall results demonstrated no statistically significant difference between study arms in progression-free or overall survival, suggesting that either treatment approach is reasonable.13 However, in a higher-risk subgroup, defined as either patients age , 70 years with stage IC or grade 3 ...
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration AbbVie and Harpoon Therapeutics announced that they have entered an immuno-oncology research collaboration. [AbbVie, Inc.] Press Release Dana-Farber Cancer Institute Joins the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy announced that researchers at Dana-Farber Cancer Institute have joined its network. Dana-Farber is a leader in cancer research and brings a team of experts who will collaborate with Parker Institute investigators to enhance and expand research projects and clinical trials. [Dana-Farber Cancer Institute] Press Release Kites Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy Kite announced that the FDA has granted regular approval to Yescarta™, the first CAR T therapy for the treatment of adult ...
Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: a pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven
Preliminary results of a Radiation Therapy Oncology Group trial (RTOG) 9705, a phase II study of postoperative adjuvant therapy in patients with completely reseted stage II and stage IIIA non-small cell lung cancer ...
Clinical trial for Malignant neoplasm of brain , An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)
Clinical trial for Malignant neoplasm of brain , An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo for Newly Diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)
To determine the long-term outcome of a consistent treatment approach with electron beam postmastectomy radiation therapy (PMRT) in breast cancer patients with , or =10 positive nodes treated with combined-modality therapy.TSixty-three breast cancer patients with , or =10 positive lymph nodes were treated with combined-modality therapy using an electron beam en face technique for PMRT at the University of Florida. Patterns of recurrence were studied for correlation with radiation fields. Potential clinical and treatment variables were tested for possible association with local-regional control (LRC), disease-free survival (DFS), and overall survival (OS).TAt 5, 10, and 15 years, OS rates were 57%, 36%, and 27%, respectively; DFS rates were 46%, 37%, and 34%; and LRC rates were 87%, 87%, and 87%. No clinical or treatment variables were associated with OS or DFS. The use of supplemental axillary radiation (SART) (p = 0.012) and pathologic N stage (p = 0.053) were associated with improved LRC. ...
Randomized. 524 patients with NSCLC Stage IIIA (33%) or resectable IIIB (67%). Arm 1) Induction cisplatin 55 mg/m2 + etoposide 100 mg/m2 x3 cycles, then concurrent RT 45/30 in 1.5 Gy BID with carboplatin 100 mg/m2 + vindesine 3mg, followed by surgery vs. Arm 2) Same induction, followed by surgery, followed by RT (54/30 if R0, 68.4/38. Surgery after 4-6 weeks. Primary endpoint PFS ...
(A) Overall survival, disease-free survival, and loco-regional control rates after definitive radiotherapy for vaginal cancer. (B, C) Overall survival and disea
Called "beige fat," the cells are found in scattered pea-sized deposits beneath the skin near the collarbone and along the spine in adult humans. Because this type of fat can burn off calories - rather than store them, as "white fat" cells do - beige fat cells might spawn new therapies for obesity and diabetes, according to researchers led by Bruce Spiegelman, PhD, of Dana-Farber.. Spiegelman is the senior author of a report scheduled for advance online publication on July 12 by the journal Cell. The print issue of Cell will publish on July 20.. The study found that beige fat is genetically distinct from "brown fat," which also burns calories to generate heat. Brown fat is found in small mammals and human infants, where it protects against harm from cold. White fat, on the other hand, stores calories, and excess white fat contributes to obesity.. Existence of this third type of fat (in addition to white and brown) had been proposed in a paper by Spiegelmans lab in 2008, but the Dana-Farber team ...
Christine Jaworek-Lopes was moved when she believed her 9-year-old son, Zachary, was writing a school paper about her experiences as a stage IV colon cancer patient at Dana-Farber/Brigham and Womens Cancer Center (DF/BWCC). Upon learning what he was really up to, she was stunned. Unbeknownst to his parents, the third-grader […] ...
Health,Scientists at the Dana-Farber Cancer Institute have identified a prote... Identification of this HIV-blocking factor opens many new avenues...,HIV,blocking,protein,in,Monkey,,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
In this manuscript, we show that treatment with low doses of fractionated radiotherapy leads to upregulation of PD-L1 expression on tumor cells secondary to CD8+ T-cell production of IFNγ. In models of melanoma, colorectal, and breast cancer, we demonstrate that the efficacy of radiotherapy can be enhanced through combination with αPD-L1 mAb, leading to the generation of memory immunity in LTS mice capable of protecting against tumor recurrence. Furthermore, our data reveal that dose scheduling may be critical for outcome with concurrent but not sequential therapy effective at improving local tumor control and survival.. Recent clinical trials have begun to evaluate blockade of the PD-1/PD-L1 axis with encouraging responses observed in multiple disease settings with mAb targeted against both PD-1 and PD-L1 (18-20, 24, 25). Despite this, combination approaches may be required to improve response rates and to generate durable antitumor immunity. We and others have demonstrated the potential to ...
Cancer survivors of all ages sometimes face psychological, social, or physical side effects that are long-lasting or develop later in life. With the number of survivors reaching 12 million in the U.S. today, the need for survivorship care and education is growing. "Survivorship care is not a one-size-fits-all approach. Just […] ...
After matching at a 1:2 ratio, 150 patients were treated with CCRT and 75 with CCRT plus C were selected. The 3-year PFS rates (83.7% vs 72.0%, P = 0.036) and 3-year LRFS rates (98.6% vs 90.2%, P = 0.034) were higher for patients in the CCRT plus C arm than with CCRT alone. Furthermore, a marginal trend of increasing risk of 3-year DMFS rates (83.9% vs 78.4%, P = 0.301) and 3-year OS rates (91.2% vs 85.8%, P = 0.123) was found. The results indicated that CCRT plus C treatment was a significant and independent protective predictor for 3-year PFS (P = 0.015) and LRFS rates(P = 0.047). When focusing on stage T4 and/or N3 in the subgroup, the CCRT plus C arm achieved significantly prolonged 3-year PFS (79.9% vs 62.6%, P = 0.022) and a marginally increased OS (88.0% vs 77.9%, P = 0.086) compared with that of CCRT alone. Additionally, the 3-year LRFS (97.0% vs 90.9%, P = 0.246) and DMFS (79.9% vs 67.8%, P = 0.161) were enhanced in patients with CCRT plus C compared to CCRT alone. When concentrating on ...
Find local Radiation Oncologists practicing in Elk City, OK. Read ratings and reviews to help find the best Radiation Oncologist in your area.
Chemotherapy is a systemic method of cancer treatment, in contrast with local therapies such as surgery and radiation therapy. The drugs used in chemotherapy are able to reach most parts of the body. Therefore, chemotherapy is likely to be recommended for cancer that has already spread to other areas of the body, for tumors that occur at more than one site, or for tumors that cannot be removed surgically. It is also used when a patient has recurrent disease after initial treatment with surgery or radiation therapy.. Chemotherapy is less mutilating than surgery and helps conserve organ or limb function since anti-cancer drugs are used to act on cancer cells without direct removal of a body part.. For some cancers, chemotherapy alone can destroy all the cancer cells and cure the cancer (primary treatment). As an adjuvant treatment, chemotherapy is given prior to, or after other methods, to increase the effectiveness of cancer treatment. Most often, adjuvant chemotherapy is given after other ...
The Ogino MPE Lab and the Program in MPE Molecular Pathological Epidemiology host the International Molecular Pathological Epidemiology (MPE) Meeting Series. ...
Find 5 local Radiation Oncologists practicing in Ypsilanti, MI. Read ratings and reviews to help find the best doctor in your area.
Find 2 local Radiation Oncologists practicing in Mission Viejo, CA. Read ratings and reviews to help find the best doctor in your area.
A number of factors may be behind underutilization of trimodality treatment in such patients, she said in an interview, emphasizing the need for criteria and the importance of developing biomarkers for IBC to help oncologists better recognize and differentiate such cancer patients at the earliest possibility.. "We need to identify these patients, especially women with aggressive IBC, and ensure they are receiving all of the treatment options available. We know that trimodality treatment is best for optimizing survival, yet many women are not being given that opportunity-for whatever reasons. Having biomarkers for IBC and implementing criteria would surely help, but right now we have neither.". The study included only women who had access to medical care who were clinically well enough to undergo aggressive treatment; excluded were those with advanced disease; those who had disease progression while on chemotherapy, rendering them nonsurgical candidates; and those in such a medically frail ...
Steven A. Rosenberg, MD In the past two decades significant progress has quality of life. The use of local radiation therapy has occurred, in the management of patients with mus- had a profound impact on the ability to achieve local loskeletal cancers, that has improved both the survival control.
Radiotherapy has been considered a local modality and outcomes have emphasized local and regional control of tumors. Recent data suggests that radiotherapy may activate the immune system and the combination of radiation therapy and immune therapies may have the potential to improve both local and distant control of tumor deposits. Below we review principals underlying the concepts of combining both modalities.
Interfacing Commitment. GE is obligated to provide Interfacing information and data (such as protocol information) necessary to ensure an open Interface between GEs existing and future devices and third parties devices in certain product combinations, and new Interfacing information relating to any Interface modification or upgrade of GEs devices.. Interfacing Commitment Overview ...
The role of radiotherapy (RT) as an adjuvant to surgical options in the treatment of locally advanced rectal cancer has been established as it reduces local recurrence when combined with surgical resection and enhances survival when used in multidisciplinary treatment. However, many issues need to be addressed; some of these can render RT unnecessary, whereas others can reveal a new role of RT in rectal cancer. This review will discuss not only the basic role of RT but also the associated but controversial issues in detail in an attempt to find answers and determine future directions for the next decade ...
Slagel, D E.; Feola, J; Houchens, D P.; and Ovejera, A A., "Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft mode." (1982). Subject Strain Bibliography 1982. 3010 ...
This randomized phase II trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy
Conclusions: The intensified treatment paradigm of XELOX concurrent chemoradiation followed by one cycle of consolidation chemotherapy was well tolerated in our cohort and provided a promising long-term oncologic outcome, which warranted further investigation in a randomize trails....
Evidence-based Series 7-3 Version [TO BE UPDATED] A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Management of Unresected Stage Ill Non-Small Cell Lung
The size, stage, rate of growth, and other characteristics of the tumor determine the kinds of treatment. Treatment may include surgery, drugs (hormonal therapy and chemotherapy), radiation and/or immunotherapy. Surgical removal of the tumor provides the single largest benefit, with surgery alone being capable of producing a cure in many cases. To somewhat increase the likelihood of long-term disease-free survival, several chemotherapy regimens are commonly given in addition to surgery. Most forms of chemotherapy kill cells that are dividing rapidly anywhere in the body, and as a result cause temporary hair loss and digestive disturbances. Radiation is indicated especially after breast conserving surgery and substantially improves local relapse rates and in many circumstances also overall survival. Some breast cancers are sensitive to hormones such as estrogen and/or progesterone, which makes it possible to treat them by blocking the effects of these hormones ...
When physician-scientist Jay Bradner left the Dana-Farber Cancer Institute last year, he left behind some key scientific work that had already intrigued a
High-dose chemotherapy can cause damage directly to the cells of the lungs. This may be more frequent in patients treated with certain types of chemotherapy and/or radiation therapy. This complication may occur anytime from a few days after high-dose chemotherapy to several months after treatment. Patients typically experience a dry, non-productive cough or shortness of breath. Sometimes, patients and their doctors often misinterpret these early symptoms. Patients experiencing shortness of breath or a new cough after allogeneic transplant should bring this to the immediate attention of their doctors since this can be a serious and even fatal complication ...
One hundred and seventy two patients with T2-3N + /-M0 distal rectal cancer had been enrolled. In Group 1 the number of patients was 127, in Group 2 - 45 patients. SSO in Group 1 comprised 43.3% in Group 2 - 91.1% (p> 0.05). A significant increase of SSO rates in women (64.5%) than men (48.9%) was observed (p = 0.04). Age, stage, tumor differentiation, the type of spread didnt affect the SSO rate. ...
Harvard researchers at Dana-Farber Cancer Institute (DFCI) have identified a number of cancer genes that endow melanoma tumors with the ability to metastasize, making it possible to predict whether the tumors are likely to spread.
Scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers, a sign that it might contribute to the disease and potentially be a key to diagnosing, preventing, and treating it ...
Highland Pharms Therapy Plus large size (4oz), an Ultra-Rich CBD Cream infused with Essential Oils for added benefit. FREE SHIPPING!
Regression of a disseminated tumour following inter-current infection and prolonged high fever was first reported by BUSCH over 100 years ago. In 1893 COLEY confirmed this observation and in a series...
New Treatment Modalities and Centers. A Brand new GammaKnife treatment center has been completed and is now available for clinical treatments. The GammaKnife Center is located on the main campus and more information can be found here. The facility construction of an innovative Proton Beam Treatment center is expected to completed by 2013. We are very excited that we will be able to provide the state of the art radiotherapy modality to the cancer patients in New Jersey and surrounding areas.. ...
Rockville, MD (PRWEB) October 19, 2010 -- CME Outfitters, LLC, (CMEO) an award-winning accredited provider of multidisciplinary continuing education (CE), is
Hi, Help! I have completed all of my care plan but cant find the multidisciplinary treatment plan for G.I. Bleeding. Upper. That was the primary diagnosis and the secondary was pancreatitis
It is well-established that nasopharyngeal carcinoma (NPC) is a chemo-responsive disease. Despite improved outcome with chemo-radiation (platimum-based chemotherapy with radiation), treatment failure continue to be a problem in patients with locally advanced Stage III/IV disease. Now, a new study published … Continue reading →. ...
In this paper we propose a multimodal approach to distinguish between movements displaying three different expressive qualities: fluid, fragmented, and impulsive movements. Our approach is based on th
Surgery for nasopharyngeal cancer is not common because the area is difficult to get to and it is close to important nerves and blood vessels. Surgery may be needed, if the cancer returns after previous treatment with radiation therapy ...
A method for co-registering multimodality imaging planes using fiducial markers is provided. A lateral transfer board which is used to move a patient f...
マッキントッシュの新しいフラッグシップスピーカーのサウンドは、その大きさに適っている。XRT2Kシリーズの次期モデルが2m以上の高さなのも頷ける。スリムなフロアスタンド型のスピーカーは、中音域とツイーターが並ぶようにしてベースキャビネットの前に掛かっている。2,000ワットものパワーはそれに匹敵するくらいのアンプを繋ぐ必要がありそうだ。...
TY - JOUR. T1 - Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.. AU - Lau, Derick H. AU - Ryu, J. K.. AU - Gandara, David R. PY - 1997/8. Y1 - 1997/8. N2 - Cisplatin-based chemoradiotherapy is becoming a standard treatment for patients with stage III non-small cell lung cancer (NSCLC). However, a significant proportion of patients with lung cancer also present with co-morbid conditions that indicate a poor prognosis and poor tolerance of treatment. We have completed a phase I/II study to evaluate the tolerability and efficacy of carboplatin-based chemoradiotherapy for patients with poor-risk stage III NSCLC. Twenty-four patients with stage IIIA/B NSCLC and concurrent medical conditions rendering them ineligible for cisplatin-based chemoradiotherapy protocols were treated with thoracic irradiation, 1.8 to 2 Gy daily to the primary tumor and regional lymph nodes, for a total dose of 61 Gy. Concurrently, patients received carboplatin 200 mg/m2/d intravenously on days 1, 3, 29, ...
TY - JOUR. T1 - Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. AU - Koshy, Matthew. AU - Malik, Renuka. AU - Spiotto, Michael. AU - Mahmood, Usama. AU - Rusthoven, Chad G.. AU - Sher, David J.. PY - 2017/6/1. Y1 - 2017/6/1. N2 - Purpose To determine the effect of radiotherapy (RT) technique on treatment compliance and overall survival (OS) in patients with stage III non-small lung cancer (NSCLC) treated with definitive chemoradiotherapy (CRT). Methods and Materials This study included patients with stage III NSCLC in the National Cancer Database treated between 2003 and 2011 with definitive CRT to 60-63 Gray (Gy). Radiation treatment interruption (RTI) was defined as a break of ≥4 days. Treatment technique was dichotomized as intensity modulated (IMRT) or non-IMRT techniques. Results Out of the cohort of 7492, 35% had a RTI and 10% received IMRT. With a median follow-up of surviving ...
Intraoperative radiation therapy, or IORT, is the application of therapeutic levels of radiation to the tumor bed while the area is exposed during surgery. IORT is typically a component in the multidisciplinary treatment of locally advanced and recurrent cancer, in combination with external beam radiation, surgery and chemotherapy. As a growing trend in recent years, IORT can also be used in earlier stage cancers such as prostate and breast cancer. IORT was found to be useful and feasible in the multidisciplinary management of many solid tumors but further studies are needed to determine the benefit more precisely. Single-institution experiences have suggested a role of IORT e.g. in brain tumors and cerebral metastases, locally advanced and recurrent rectal cancer, skin cancer, retroperitoneal sarcoma, pancreatic cancer and selected gynaecologic and genitourinary malignancies. For local recurrences, irradiation with IORT is, besides brachytherapy, the only radiotherapeutic option if repeated ...
New York-Presbyterian/Columbia University Medical Center is one of the first institutions in the New York metropolitan area to offer intraoperative radiation therapy (IORT), which entails a single dose of radiation therapy that is administered immediately after lumpectomy. This innovative breast cancer therapy became available at the BreastCenter during the summer of 2013.
Intraoperative radiation therapy (IORT) has been customarily performed either in a shielded operating suite located in the operating room (OR) or in a shielded treatment room located within the Department of Radiation Oncology. In both cases, this cancer treatment modality uses stationary linear accelerators. With the development of new technology, mobile linear accelerators have recently become available for IORT. Mobility offers flexibility in treatment location and is leading to a renewed interest in IORT. These mobile accelerator units, which can be transported any day of use to almost any location within a hospital setting, are assembled in a nondedicated environment and used to deliver IORT. Numerous aspects of the design of these new units differ from that of conventional linear accelerators. The scope of this Task Group (TG-72) will focus on items that particularly apply to mobile IORT electron systems. More specifically, the charges to this Task Group are to: i) identify the key ...
TY - JOUR. T1 - Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer. T2 - CALGB 31102 (Alliance). AU - Urbanic, James J.. AU - Wang, Xiaofei. AU - Bogart, Jeffrey A.. AU - Stinchcombe, Thomas E.. AU - Hodgson, Lydia. AU - Schild, Steven E.. AU - Bazhenova, Lyudmila. AU - Hahn, Olwen. AU - Salgia, Ravi. AU - Vokes, Everett E.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Purpose: To investigate the safety of accelerated hypofractionated radiation therapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small cell lung cancer (NSCLC). Patients and Methods: The primary objectives were to define the maximally tolerable course of accelerated radiation therapy and to describe toxicities of therapy. Total radiation therapy remained at 60 Gy. The number of once-daily fractions in each successive cohort was reduced as follows: cohort 1, 60 Gy in 27 fractions; cohort 2, 60 Gy in 24 fractions; cohort 3, 60 Gy in 22 ...
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in women with breast cancer. Targeted intraoperative radiotherapy met the noninferiority margin for 5-year local recurrence among all patients and when given concurrently with lumpectomy but not when delayed until after lumpectomy (postpathology). Breast cancer mortality did not differ significantly between the two groups, but targeted intraoperative radiotherapy was associated with reduced non-breast cancer mortality.. Study Details. In this open-label, randomized trial, 3,451 women aged ≥ 45 years with invasive ductal carcinoma were randomly assigned to receive single-dose targeted intraoperative radiotherapy (n = 1,721) or whole-breast external-beam radiotherapy according to standard schedules over ...
Looking for online definition of autologous bone marrow transplantation in the Medical Dictionary? autologous bone marrow transplantation explanation free. What is autologous bone marrow transplantation? Meaning of autologous bone marrow transplantation medical term. What does autologous bone marrow transplantation mean?
PURPOSE The survival advantage of preoperative radiotherapy in patients with rectal cancer is still a matter of debate, because its incremental benefit in the total mesorectal excision setting is unclear. This study was designed to evaluate early and long-term results of preoperative radiotherapy plus intraoperative radiotherapy in a homogeneous population of T3 middle and lower rectal cancer patients submitted to total mesorectal excision. METHODS A series of 113 patients with middle and lower T3 rectal cancer consecutively submitted to total mesorectal excision at a single surgical unit from 1991 to 1997 were divided into two groups according to type of neoadjuvant treatment: preoperative radiotherapy (38 Gy) plus intraoperative radiotherapy (10 Gy; n = 69), and no preoperative treatment (total mesorectal excision; n = 44). Standard statistical analyses were used to evaluate early (downstaging, intraoperative factors, hospital morbidity, and mortality rates) and long-term results (recurrence and
U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03111069) titled Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children on April 6. Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied. Study Start Date: Study Type: Interventional Condition: Malignant Neoplasms of Mesothelial and Soft Tissue Rhabdomyosarcoma, Pelvic Rhabdomyosarcoma, Abdominal Intervention: Procedure: Abdominal Surgery Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease). Unresectable Intra-Abdominal/Pelvic Tumors Group: ...

Modification of Radiosensitivity Following Chemotherapy Exposure: Potential Implications for Combined-Modality Therapy |...Modification of Radiosensitivity Following Chemotherapy Exposure: Potential Implications for Combined-Modality Therapy |...

Cervical Cancer Radiation Response Small Cell Lung Cancer Cell Combine Modality Therapy Human Ovarian Cancer Cell Line These ... Sersa G, Kranjc S, Cemazar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of ... Modification of Radiosensitivity Following Chemotherapy Exposure: Potential Implications for Combined-Modality Therapy. ... Potential Implications for Combined-Modality Therapy. In: Andersson B., Murray D. (eds) Clinically Relevant Resistance in ...
more infohttps://link.springer.com/chapter/10.1007/978-1-4615-1173-1_14

Combined Modality Therapy of Gastrointestinal Tract Cancer | SpringerLinkCombined Modality Therapy of Gastrointestinal Tract Cancer | SpringerLink

Modern surgical oncology is characterized by multimodal therapy. In recent years numerous therapeutic approaches of pre-, peri ... Combined Therapy in Gastric Cancer. * Phase-III Clinical Trial of Adjuvant FAM2 (5-FU, Adriamycin and Mitomycin C) vs Control ... Combined Therapy in Esophageal Cancer. * The Value of Preoperative Radiotherapy in Esophageal Cancer: Results of a Study by the ... Combined Therapy in Colorectal Cancer. * Adjuvant Portal Infusion Chemotherapy in Colorectal Cancer ...
more infohttps://link.springer.com/book/10.1007%2F978-3-642-83293-2

Docetaxel and Radiation as Combined-Modality Therapy | Cancer Network | The Oncology JournalDocetaxel and Radiation as Combined-Modality Therapy | Cancer Network | The Oncology Journal

Combined-modality approaches for the treatment of non-small-cell lung cancer (NSCLC), head and neck cancer, and esophageal ... combined-modality therapy.. Background. The taxanes are a class of antineoplastic agents, derived from plants, that. have ... Mauer AM, Haraf DC, Ferguson MK, et al: Docetaxel-based combined modality. therapy for locally advanced carcinoma of the ... have included single modalities such as surgery, radiation, or chemotherapy.. Combined modality approaches offer a theoretical ...
more infohttp://www.cancernetwork.com/review-article/docetaxel-and-radiation-combined-modality-therapy

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma - Full Text View - ClinicalTrials.govIdarubicin Based Combined Modality Therapy in Primary CNS Lymphoma - Full Text View - ClinicalTrials.gov

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma. The safety and scientific validity of this study is the ... Combined modality therapy in PCNSL has improved survival outcomes but at the cost of unacceptable rates of neurotoxicity when ... A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma. ... By combining these 2 drugs with moderate dose radiotherapy survival outcomes should be optimal but with lower rates of ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00193973?cond=%22Central+Nervous+System+Lymphoma%22&intr=%22Vitamin+B+Complex%22&rank=7

PRIME PubMed | [Combined-modality therapy for 150 cases of early-stage Hodgkins lymphomaPRIME PubMed | [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma

Combined-modality therapy for 150 cases of early-stage Hodgkins lymphoma were found in PRIME PubMed. Download Prime PubMed App ... Combined-modality Therapy for 150 Cases of Early-stage Hodgkins Lymphoma]." Zhonghua Zhong Liu Za Zhi [Chinese Journal of ... Combined-modality Therapy for 150 Cases of Early-stage Hodgkins Lymphoma]. Zhonghua Zhong Liu Za Zhi. 2008;30(8):630-4. PubMed ... Combined-modality therapy for 150 cases of early-stage Hodgkins lymphoma].. Zhonghua Zhong Liu Za Zhi 2008; 30(8):630-4ZZ ...
more infohttps://www.unboundmedicine.com/medline/citation/19102946/%5BCombined_modality_therapy_for_150_cases_of_early_stage_Hodgkin

Combined-Modality Therapy for Head and Neck Cancer | Cancer Network | The Oncology JournalCombined-Modality Therapy for Head and Neck Cancer | Cancer Network | The Oncology Journal

... when combined with radiotherapy and/or surgery in the treatment of patients with head and neck cancer, appears to be most ... This paper presents an overview of the results of randomized trials of combined-modality therapy for advanced head and neck ... Lo TC, Wiley AL, Jr., Ansfield FJ, et al: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of ... Adelstein DJ, Sharan VM, Earle AS, et al: Simultaneous versus sequential combined technique therapy for squamous cell head and ...
more infohttp://www.cancernetwork.com/review-article/combined-modality-therapy-head-and-neck-cancer-1

Combined modality therapy for esophageal cancer<...Combined modality therapy for esophageal cancer<...

Blanke, C. D. ; Choy, H. ; Leach, S. D. / Combined modality therapy for esophageal cancer. In: Seminars in Radiation Oncology. ... Blanke, C. D., Choy, H., & Leach, S. D. (1997). Combined modality therapy for esophageal cancer. Seminars in Radiation Oncology ... Blanke, CD, Choy, H & Leach, SD 1997, Combined modality therapy for esophageal cancer, Seminars in Radiation Oncology, vol. 7 ... Combined modality therapy for esophageal cancer. Seminars in Radiation Oncology. 1997;7(3 SUPPL. 2):15-23. ...
more infohttps://jhu.pure.elsevier.com/en/publications/combined-modality-therapy-for-esophageal-cancer-3

A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.govA Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.gov

A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer. The safety and scientific validity of this ... Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy ... Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated. ... HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible ...
more infohttps://clinicaltrials.gov/show/NCT00149578

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Full Text View -...Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Full Text View -...

I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) ... Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer. The safety and ... A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer. ... This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT03233711?cond=CMT&rank=50

Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer - Non-Small Cell Lung Cancer and Tracheal Cancer:...Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer - Non-Small Cell Lung Cancer and Tracheal Cancer:...

Adjuvant Therapy for Non-Small Cell Lung Cancer14:58. Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer ... Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer. To view this video please enable JavaScript, and ... This lecture is going to be dealing with the combined-modality therapy for patients with locally advanced non-small cell lung ... Majority of people will undergo combined-modality therapy with a curative intent. Cure is achieved in approximately 20 percent ...
more infohttps://www.coursera.org/lecture/thoracic-oncology/combined-modality-therapy-for-locally-advanced-non-small-cell-lung-cancer-itah3

Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative...Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative...

Functional and quality-of-life outcomes in patients with rectal cancer after combined modality therapy, intraoperative ... The majority of patients with advanced rectal cancers who require external beam radiation therapy, extensive pelvic surgery, ... Locally advanced primary and recurrent rectal cancers treated with external beam radiation therapy, intraoperative radiation ... and intraoperative radiation therapy report unfavorable functional and quality-of-life outcomes after sphincter preservation. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/10859073

IJMS | Free Full-Text | Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic...IJMS | Free Full-Text | Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic...

In view of the complexity of biological responses to cancer therapy, this communication reports on a ... Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the ... Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies ... Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, ...
more infohttp://www.mdpi.com/1422-0067/15/12/22835

Combined modality therapy in non-small cell lung cancer<...Combined modality therapy in non-small cell lung cancer<...

Blanke, C., & Johnson, D. H. (1995). Combined modality therapy in non-small cell lung cancer. Current Opinion in Oncology, 7(2 ... Blanke, C & Johnson, DH 1995, Combined modality therapy in non-small cell lung cancer, Current Opinion in Oncology, vol. 7, ... Blanke, Charles ; Johnson, D. H. / Combined modality therapy in non-small cell lung cancer. In: Current Opinion in Oncology. ... title = "Combined modality therapy in non-small cell lung cancer",. abstract = "Lung cancer kills more Americans annually than ...
more infohttps://ohsu.pure.elsevier.com/en/publications/combined-modality-therapy-in-non-small-cell-lung-cancer-2

Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report | BMC Pulmonary Medicine | Full...Combined-modality therapy for pulmonary alveolar proteinosis in a remote setting: a case report | BMC Pulmonary Medicine | Full...

We posit that this combined-modality therapy is ideally suited to geographically-remote centers such as our own. ... The autoimmune form of PAP is the most common, indicating that therapy with GM-CSF may play an important role for many patients ... Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen ... Treatment with WLL may be impractical in some clinical settings due to the expertise and salvage modalities required. ...
more infohttps://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-019-0822-x?optIn=false

Download Combined Modality Therapy Of Central Nervous System TumorsDownload Combined Modality Therapy Of Central Nervous System Tumors

... The download combined modality therapy of of Malory ... This recipient public download combined modality therapy of, of gp, is moved in the Idyll. This download combined modality will ... Can I use or Exchange a download combined modality therapy of central after I suggest it? Because the download combined ... The download combined modality therapy and formula of Lancelot pass up to the later paper of his language. But this course is ...
more infohttp://sierrasignsaz.com/images/ebooks/download-combined-modality-therapy-of-central-nervous-system-tumors.html

Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy...Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy...

Seung, S. K., & Ross, H. J. (2009). Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy ... Seung, SK & Ross, HJ 2009, Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by ... Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy ... Phase II Trial of Combined Modality Therapy With Concurrent Topotecan Plus Radiotherapy Followed by Consolidation Chemotherapy ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/phase-ii-trial-of-combined-modality-therapy-with-concurrent-topot

Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma | NCCN Continuing EducationContemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma | NCCN Continuing Education

... establishing combined modality therapy as the standard of care for most patients with this disease. In response, significant ... Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ... interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized ...
more infohttps://education.nccn.org/node/65996

Combined modality therapy for thoracic and head and neck cancers: A review of updated literature based on a consensus meeting<...Combined modality therapy for thoracic and head and neck cancers: A review of updated literature based on a consensus meeting<...

Combined modality therapy for thoracic and head and neck cancers: A review of updated literature based on a consensus meeting. ... Combined modality therapy for thoracic and head and neck cancers : A review of updated literature based on a consensus meeting. ... T1 - Combined modality therapy for thoracic and head and neck cancers. T2 - A review of updated literature based on a consensus ... Combined modality therapy for thoracic and head and neck cancers: A review of updated literature based on a consensus meeting. ...
more infohttps://moh-it.pure.elsevier.com/en/publications/combined-modality-therapy-for-thoracic-and-head-and-neck-cancers--2

Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality TherapyOncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy

... ... Salvage surgery after failed chemoradiation therapy has a reasonable chance of cure. Favorable independent prognostic factors ... Salvage inguinal lymph node dissection after failed chemoradiation therapy also is potentially curative. ...
more infohttps://insights.ovid.com/dcolr/200447070/00003453-200447070-00003

A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].<...A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].<...

A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. In: Gan to kagaku ryoho. ... A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. Gan to kagaku ryoho. ... A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer]. / Hasegawa, Hirofumi; ... title = "[A case of long-term survival due to combined modality therapy for liver metastasis of colon cancer].", ...
more infohttps://kyushu-u.pure.elsevier.com/en/publications/a-case-of-long-term-survival-due-to-combined-modality-therapy-for

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer ...Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer ...

The most frequent side-effect of the preoperative combined therapy was dermatitis (grade 3 in 19 patients). The proportion of ... Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer ... Kocakova I, Svoboda M, Klocova K, Chrenko V, Roubalova E, Krejci E, Sefr R, Slampa P, Frgala T, Zaloudik J: Combined therapy of ... The most frequent side-effect of the preoperative combined therapy was dermatitis (grade 3 in 19 patients). The proportion of ...
more infohttps://ro-journal.biomedcentral.com.preview-live.oscarjournals.springer.com/articles/10.1186/1748-717X-5-88

A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy:...A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy:...

Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced ... Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer ... Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced ... A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy ...
more infohttps://pubrank.carbocation.com/pmid/17197970

Story Lab - UT SouthwesternStory Lab - UT Southwestern

Combined modality therapy. The third area of biology we are focused on is referred to as combined modality therapy. Our goal is ... We are examining circulating miRNA for response to therapy and metastatic potential using a relatively non-invasive method. And ... center at UT Southwestern that includes the construction of a proton therapy center as well as a heavy particle therapy center ... and medicine that will contribute to the use of heavy particles for therapy. We are collaborating with the GSI Helmholtz Centre ...
more infohttps://www.utsouthwestern.edu/labs/story/

Plus itPlus it

Single-modality therapy does not have a major impact on long-term survival and combined-modality therapies are being further ... Combined-modality therapy. Even 30 years ago, it was clear that MPM is difficult to treat and that, for most patients, there is ... Is trimodal therapy a valid option for patients with mesothelioma that is technically resectable? Different combined-modality ... Further prospective trials are required to determine optimal combined modality therapy in mesothelioma. Hopefully, the ...
more infohttps://erj.ersjournals.com/content/44/3/754

Health Information CenterHealth Information Center

Combined Modality Therapy. Most times, pancreatic cancer is discovered at an advanced stage. Surgery may not be appropriate in ... Radiation Therapy. This is the use of radiation to kill cancer cells and shrink tumors. Radiation therapy may be:. *External- ... The physical exam combined with all of your test results, will help to determine the stage of cancer you have. Staging is used ... Biological Therapy. The use of medications or substances made by the body. They can increase or restore the bodys natural ...
more infohttps://healthlibrary.epnet.com/GetContent.aspx?token=35cd8c16-7dff-43e2-92cc-6a1c93b5abd4&chunkiid=11635
  • Methods: The Italian Association of Radiation Oncology Young Members Working Group (AIRO Giovani) organized its 8th national meeting, focused on combination therapy in lung, esophageal, and head and neck cancer (with a specific focus on larynx-preservation strategies for larynx/hypopharynx tumors), involving young professionals working in Italy. (elsevier.com)
  • Additional sequential lobar lavage and continued GM-CSF therapy as an outpatient resulted in complete resolution of oxygen requirement and return to normal pulmonary physiology. (biomedcentral.com)
  • More Americans will die from lung cancer each year (approximately 159,480) than from colon, breast, pancreatic, and prostate cancer combined (approximately 158,630), the next most common causes of cancer death. (coursera.org)
  • We retrospectively reviewed our experience with locally advanced primary and recurrent rectal cancer patients who underwent intraoperative radiation therapy with either low anterior resection (n = 12) or coloanal anastomosis (n = 6) between 1991 and 1998. (nih.gov)
  • Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the individual patient. (mdpi.com)
  • In response, significant interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized while still preserving disease control. (nccn.org)
  • Conclusions: Combination therapy has proved to be a consolidated approach in these specific oncologic settings, highlighting the importance of multimodality management in modern clinical oncology. (elsevier.com)
  • Single-modality therapy is the standard for most cases of limited and metastatic non-small cell lung cancer, but treatment of locally advanced disease remains controversial. (elsevier.com)
  • Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ability to better customize treatment regimens to individual patients. (nccn.org)
  • The prognosis of patients with malignant pleural mesothelioma remains poor and although it is clear that multimodal therapy is necessary to improve long-term results, precise treatment schemes have not yet been unequivocally established. (ersjournals.com)
  • Although it has not been shown that chemo- and radiation therapy at the same time are better than radiation therapy alone in the treatment of gallbladder cancer, CMT is better with many other kinds of cancers. (doctors-hospital.net)
  • Patients with stage III prostate cancer are curable and have a number of treatment options, including external beam radiation therapy (EBRT) with or without hormone therapy, surgical removal of the cancer with radical prostatectomy, or active surveillance without immediate treatment. (yourcancercare.com)
  • The current standard treatment for stage III prostate cancer is external beam radiation therapy (EBRT) in conjunction with long-term androgen deprivation therapy (ADT). (yourcancercare.com)
  • Treatment with surgery or radiation is referred to as local therapy because they treat prostate cancer in or near the prostate only. (yourcancercare.com)
  • An effective treatment is needed to cleanse the body of micrometastases in individuals at high risk of recurrence after local therapy. (yourcancercare.com)
  • Another form of treatment, usually hormone therapy, radiation therapy or participation in a clinical study is generally recommended. (yourcancercare.com)
  • In the TNM system, only anatomical features are taken into consideration and, as precise anatomical landmarks are surgically driven, this system has several limitations because most patients with mesothelioma will not undergo extensive surgical therapy. (ersjournals.com)
  • Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients. (elsevier.com)
  • The objectives of the talk are to review the role of systemic therapy in locally advanced non-small cell and to review the role of combined-modality therapy in people with locally advanced non-small cell lung cancer. (coursera.org)
  • Topotecan is active against NSCLC, can safely be combined with RT at effective systemic doses, and can be given by continuous infusion, making it an attractive study agent against locally advanced NSCLC. (elsevier.com)
  • The majority of patients with advanced rectal cancers who require external beam radiation therapy, extensive pelvic surgery, and intraoperative radiation therapy report unfavorable functional and quality-of-life outcomes after sphincter preservation. (nih.gov)
  • In view of the complexity of biological responses to cancer therapy, this communication reports on a "top-down" strategy, starting with the systematic assessment of adverse effects within a defined therapeutic context and proceeding to transcriptomic and proteomic analysis of relevant patient tissue samples and computational exploration of the resulting data, with the ultimate aim of utilizing information from functional connectivity networks in evaluation of patient safety in multimodal cancer therapy. (mdpi.com)
  • 25,Based on these preclinical results, phase I investigations of docetaxel with concurrent radiation therapy were initiated. (cancernetwork.com)
  • The physical exam combined with all of your test results, will help to determine the stage of cancer you have. (epnet.com)
  • Blanke, C & Johnson, DH 1995, ' Combined modality therapy in non-small cell lung cancer ', Current Opinion in Oncology , vol. 7, no. 2, pp. 144-149. (elsevier.com)